Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced a significant advancement in its ongoing clinical trial for Stargardt disease. The Data Safety and Monitoring Board (DSMB) for the …
Ocugen’s OCU410ST Advances in Clinical Trial for Stargardt Disease, Moving to Medium Dose Testing Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies, recently announced the appointment of Dr. Huma Qamar as its Chief Medical …
Ocugen, Inc. Welcomes Dr. Huma Qamar as New Chief Medical Officer to Spearhead Clinical Developments Read More MALVERN, PA — Ophthalmology is on the crest of a wave; a paradigm shift heralded by Ocugen, Inc (NASDAQ: OCGN) may be imminent. The Pennsylvania-based biopharmaceutical firm recently crossed a …
Ocugen’s Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the Horizon Read More MALVERN, PA — In a promising development for the treatment of Stargardt disease, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company based in Chester County, Pennsylvania, has announced the completion of …
Ocugen Achieves Clinical Milestone in Stargardt Disease Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a frontrunner in the biotechnology industry, announced that its Chairman, Chief Executive Officer, and Co-Founder, Dr. Shankar Musunuri, will present at the highly …
Ocugen CEO to Present at Prestigious BIO CEO & Investor Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a pioneer in the biotechnology field, is set to hold an in-person Clinical Showcase on February 21, 2024, at the Nasdaq Market Site …
Ocugen to Spotlight Promising Gene Therapy in Clinical Showcase Read More MALVERN, PA — Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, Inc. (NASDAQ: OCGN), is set to deliver a keynote speech at the upcoming Pharma Market Research Conference (PMRC) …
Ocugen CEO to Deliver Keynote on Future Healthcare Innovations at PMRC 2024 Read More MALVERN, PA — In a strategic move aimed at expanding its global footprint, Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies, has welcomed …
Ocugen Bolsters Business Advisory Board with Former Pfizer Executive, Eyes Global Expansion Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, recently announced that it has received alignment from the U.S. Food and Drug Administration (FDA) on the design of a …
Ocugen Gains FDA Alignment for Phase 3 Trial of Retinitis Pigmentosa Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a Pennsylvania-based biopharmaceutical company, has scored a significant regulatory milestone this week with the U.S. Food and Drug Administration (FDA) granting Regenerative Medicine …
Ocugen’s OCU400 Earns FDA’s RMAT Designation, Enhancing Prospects for Retinitis Pigmentosa Treatment Read More